Table 2.
Antibody array data for proteins activated by insulin stimulation and attenuated by pre-treatment of HepG2 cells with PMA.
| Ratio a | ||
|---|---|---|
| Name | Insulin | PMA+Insulin |
| 4E-BP1(Thr36) | 1.51 | 1.19 |
| 4E-BP1(Thr45) | 7.68 | 4.78 |
| Akt(Ser473) | 2.03 | 1.24 |
| Akt(Thr308) | 1.51 | 0.97 |
| Akt2(Ser474) | 1.28 | 0.86 |
| AMPK1/AMPK2(Ser485/Ser491) | 1.28 | 0.84 |
| BAD(Ser112) | 1.52 | 0.91 |
| BAD(Ser136) | 1.13 | 0.63 |
| BAD(Ser155) | 2.02 | 0.97 |
| c-Jun(Ser63) | 0.85 | 0.60 |
| eIF2α(Ser51) | 1.46 | 0.77 |
| FOXO1a(Ser256) | 1.35 | 0.87 |
| FOXO1a(Ser319) | 2.21 | 0.81 |
| FOXO3(Ser253) | 0.89 | 0.47 |
| FOXO4(Ser197) | 2.01 | 1.70 |
| GSK3β(Ser9) | 2.21 | 0.82 |
| IκB-α(Ser32/Ser36) | 1.05 | 0.85 |
| MEK1(Ser217) | 1.60 | 1.10 |
| MEK1(Ser221) | 1.59 | 0.96 |
| MEK1(Thr291) | 1.29 | 1.12 |
| MEK-2(Thr394) | 1.80 | 1.29 |
| p38 MAPK(Thr180) | 1.24 | 0.68 |
| p44/42 MAP Kinase(Thr202) | 1.51 | 1.03 |
| p44/42 MAP Kinase(Tyr204) | 1.61 | 1.15 |
| p70 S6 Kinase (Ser424) | 1.50 | 0.96 |
| p70 S6 Kinase(Ser411) | 1.65 | 1.04 |
| PDK1(Ser241) | 1.65 | 0.82 |
| PKR(Thr446) | 0.94 | 0.77 |
| PKR(Thr451) | 1.97 | 1.04 |
| PTEN(Ser370) | 2.37 | 1.27 |
| Raf1(Ser259) | 2.09 | 1.48 |
| Raf1(Ser338) | 1.23 | 1.00 |
| S6 Ribosomal Protein(Ser235) | 1.51 | 1.06 |
a
For each treatment group, the phosphorylation signal ratio induction was calculated and further normalized by the ratio obtained from the untreated, control group, which was given a value of 1. The coefficients of variation for the fluorescence intensity are ≤ 6% from replicate spots and arrays; the CVs of phosphorylation signal ratio induction are therefore ≤ 12 %. The statistical analysis shows that the ratio change between insulin and PMA pretreatment followed by insulin treatment is significant with p < 0.05.